PURPOSE: To examine the evidence concerning the safety and effectiveness of the
inactivated hepatitis A virus vaccine recently licensed for use in Canada. DATA SOURCES …

The first identification of hepatitis A virus (HAV) in stool specimens occurred in 1973 [1].
Successful isolation and propagation of HAV in cell culture [2a, b] made the development of …

Studies were conducted on the preparation, inactivation, safety, and immunogenicity of a
prototype hepatitis A virus vaccine prepared from infected cell cultures. BS-C-1 cells …

The prevention of hepatitis A virus (HAV) infection should be greatly facilitated with the
expected licensure of inactivated hepatitis A vaccines. In countries with a low endemicity of …

The objectives for the clinical testing of the inactivated hepatitis A vaccine developed by
SmithKline Beecham Biologicals are reviewed and the results obtained are summarized …

Hepatitis A vaccine, strain HM175, was investigated for immunogenicity and tolerability in a
prospective multicentre trial. The following vaccination schedules and antigen contents were …

To determine the safety and immunogenicity of an inactivated hepatitis A vaccine, 56 healthy
adult volunteers were randomly assigned to receive an intramuscular injection of 6.3, 12.5 or …

The safety and immunogenicity of an inactivated hepatitis A vaccine (HMI75) were evaluated
in 151 seronegative health professionals (age range, 21–65 years; mean, 30). A 720-ELISA …

An inactivated vaccine against hepatitis A was administered as a single 1,440 enzyme‐
linked immunosorbent assay (ELISA) units dose at month 0 with a booster at month 6 to 200 …

An inactivated hepatitis A virus (HAV) vaccine was tested on a group of human adult
volunteers. The vaccine was administered subcutaneously, and a control group received a …